CDK4/6 inhibition has been shown to affect signaling in all three pathways [42–44] suggesting a possible mechanism whereby G1T38 reverses the resistance of erlotinib in EGFR mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.